Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: DVS-SR 50 mg
DRUG: DVS-SR 100 mg
DRUG: Placebo

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer